Analysts Set Intensity Therapeutics Inc. (NASDAQ:INTS) Price Target at $37.50

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have earned an average recommendation of “Moderate Buy” from the four analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $37.50.

Several research analysts have issued reports on the company. Wall Street Zen upgraded Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Freedom Capital upgraded Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 30th. Benchmark restated a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. Finally, Weiss Ratings lowered Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Corient Private Wealth LLC purchased a new position in shares of Intensity Therapeutics during the fourth quarter valued at approximately $41,000. State Street Corp boosted its position in shares of Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares during the period. Jane Street Group LLC purchased a new position in shares of Intensity Therapeutics during the fourth quarter valued at approximately $26,000. Geode Capital Management LLC boosted its position in shares of Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after buying an additional 201,357 shares during the period. Finally, Mesirow Financial Investment Management Inc. boosted its position in shares of Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after buying an additional 51,000 shares during the period. Hedge funds and other institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Trading Down 6.3%

Shares of NASDAQ INTS opened at $4.01 on Thursday. The business’s 50 day moving average is $5.15 and its two-hundred day moving average is $7.83. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.86 and a quick ratio of 4.86. Intensity Therapeutics has a 1-year low of $3.95 and a 1-year high of $43.50. The stock has a market capitalization of $10.83 million, a P/E ratio of -0.70 and a beta of 2.77.

Intensity Therapeutics (NASDAQ:INTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, topping the consensus estimate of ($1.08) by $0.12. As a group, research analysts expect that Intensity Therapeutics will post -2.7 EPS for the current year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.